You are here

Angiochem to present at Cowen and Company 30th Annual Health Care Conference

05-Mar-2010

Montreal, Canada – Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that Queenie Jang, Angiochem’s VP of Corporate Development, will present at the Cowen and Company 30th Annual Health Care Conference on Wednesday, March 10, 2010, at 2:30p.m. EST in the MIT room, 3rd floor at the Boston Marriott Copley Place in Boston, Massachusetts.

Ms. Jang will provide attendees with an update on Angiochem and its product pipeline, including its lead drug candidate, ANG1005, which has demonstrated a favorable safety and efficacy profile in over 100 subjects with brain cancer from two separate clinical studies, including recurrent glioblastoma and progressive brain metastases.

About ANG1005 // ANG1005 has a novel mode of action, targeting the lipoprotein receptor-related protein (LRP-1) pathway. ANG1005 was created with the Engineered Peptide Compounds (EPiC) platform which leverages the LRP-1 mediated pathway. Studies have shown that ANG1005 gains entry into the brain by targeting LRP-1, one of the most highly expressed receptors on the surface of the BBB. ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including gliomas, Breast , Lung, Liver and Ovarian cancers.

About AngioChem //Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier (BBB) to treat brain diseases. The company’s proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that cross the BBB and reach therapeutic concentration in the brain, by harnessing naturally-occurring receptors on the surface of the BBB. Angiochem’s lead product candidate, ANG1005 is in two separate clinical studies in patients with brain cancers and cancer metastases. Additionally, Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic diseases, brain cancer, psychiatric disorders and many others. Founded in 2006, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit: http://www.angiochem.com.